Study finds specific gut microbiota signature is associated with vulnerability to food addiction

Ake­bia now ex­pects to re­file its chron­ic kid­ney dis­ease treat­ment vadadu­s­tat by the end of Sep­tem­ber. The biotech said Thurs­day morn­ing that it had a

Plus, news about OP­KO, Health­Care Roy­al­ty, In­ven­ti­va, Ex­sci­en­tia and GT Ape­iron: Boehringer In­gel­heim ups its R&D bud­get: Back in April, the com­pa­ny said it …

When launch­ing a new drug, phar­ma com­pa­nies of­ten fo­cus on tan­gi­ble tar­gets like aware­ness, mes­sage re­call or num­ber of sales rep in­ter­ac­tions and time spent